L
Linda Ashcroft
Researcher at Manchester Academic Health Science Centre
Publications - 63
Citations - 2460
Linda Ashcroft is an academic researcher from Manchester Academic Health Science Centre. The author has contributed to research in topics: Lung cancer & Breast cancer. The author has an hindex of 28, co-authored 63 publications receiving 2150 citations. Previous affiliations of Linda Ashcroft include National Health Service & University of Manchester.
Papers
More filters
Journal ArticleDOI
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn,Michael Snee,Linda Ashcroft,W. Appel,Fabrice Barlesi,Adityanarayan Bhatnagar,Andrea Bezjak,Felipe Cardenal,Pierre Fournel,Susan Harden,Cécile Le Péchoux,Rhona McMenemin,Nazia Mohammed,Mary O'Brien,Jason Pantarotto,Veerle Surmont,Jan P. van Meerbeeck,Penella J. Woll,Paul Lorigan,Fiona H Blackhall +19 more
TL;DR: Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens.
Journal ArticleDOI
Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
D. G. R. Evans,Fiona Lalloo,Linda Ashcroft,A Shenton,Thomas E. Clancy,Andrew D Baildam,A. Brain,P. Hopwood,Anthony Howell +8 more
TL;DR: To truly assess the uptake of risk-reducing surgery, longer-term follow-up is necessary particularly in younger women who are likely to delay BRRSPO, although careful risk counseling does seem to influence women's decisions for surgery, although the effect is not immediate.
Journal ArticleDOI
ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer
TL;DR: ERCC1 mRNA expression in advanced NSCLC did not favor a prognostically better outcome after platinum-based chemotherapy, and potential reasons are explored, including the need for cautious interpretation of mRNA expression data from archival materials.
Journal ArticleDOI
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
Mark R. Middleton,Paul Lorigan,J Owen,Linda Ashcroft,Siow Ming Lee,Peter Harper,Nick Thatcher +6 more
TL;DR: DBCT combination therapy cannot be recommended as standard treatment for advanced melanoma because it was associated with significantly greater haematological toxicity, and a greater need for time spent in hospital.
Journal ArticleDOI
The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit
Paul Wheatley-Price,Clement Ma,Linda Ashcroft,M. Nankivell,Richard Stephens,Shane C White,Paul Lorigan,Nick Thatcher,Fiona H Blackhall,Frances A. Shepherd +9 more
TL;DR: Data from >1700 patients in randomized SCLC chemotherapy trials confirm that women survive modestly longer than men but may experience greater toxicity when treated for small-cell lung cancer.